Naloxone Market

2021-2030 Analysis and Review Naloxone Market

Naloxone Market

Naloxone Market By Formulation/Route of administration (Parenteral, Intranasal, Sublingual) By Dosage/Strength (0.4mg/ml, 1mg/1ml, 0.4mg/0.4ml, 4 mg/0.1 ml) By Sales Channel (hospital pharmacy, outpatient retail pharmacy, online pharmacy, others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021 – 2030

17-09-2021 REP-HC-139287 120 pages Format

The Naloxone market is projected to grow at a CAGR of 10.5% during the forecast period from 2021 to 2030. Naloxone is an opioid antagonist designed to rapidly reverse opioid overdose. Naloxone can restore the normal respiration of a person whose breathing has stopped or slowed down due to opioid or heroin overdose. Currently, opioid abuse is one of the foremost causes of drug overdose and is a leading cause of death globally. However, it is more common in North America and Europe. The opioid crisis in the U.S. has reached epidemic proportions, leading to serious healthcare costs and losses of resources. The urgent need for better treatment and growth in numbers of people suffering from opioid dependence is resulting in the growth in the U.S. naloxone market. Opioid dependence is a serious concern globally, with more than 25 million people affected. The problem exists in both developed as well as developing countries but is greatest in the United States.

Naloxone Market

Increasing prevalence of opioid overdoses

The increasing prevalence of opioid overdoses is expected to drive the growth of the naloxone market. An increasing incidence of opioid drug abuse in both the developed and developing worlds remains the key driver for the market growth of the naloxone market. On average, more than 130 people in America die each day from an opioid overdose. Opioids are a class of drugs that include even prescription drugs such as oxycodone, fentanyl, morphine, and hydrocodone. It also includes illegal drugs such as heroin or drugs sold as heroin. The use of opioids for chronic pain management has increased worldwide. This has further increased the non-medical use of opioids due to their addictive characteristics. The number of drug overdose deaths increased by almost 5% between 2018 and 2019. The above trends signify the need for naloxone to mitigate the risks of death from an opioid overdose. 

Parenteral route of Naloxone Administration Dominates

Based on the formulation/route of administration, the naloxone market is categorized as parenteral, intranasal, and sublingual. The parenteral segment contributed highest to the market revenues. Hospitals still remain the key resort when individuals are overdosed, and parenteral remains the key preferred administration method among healthcare professionals. The sublingual route stands second followed by the parenteral route. Sublingual options have been tested and efficiency proven across decades and also, intake does not require the help of a healthcare professional. Therefore, this route is convenient for emergency use. However, during the forecast period, there have been significant changes in the market compared to the base year of 2021.

0.4mg/ml Remains as The Most Adopted Dosage

Based on dosage/strength, the naloxone market is segmented into 0.4mg/ml, 1mg/1ml, 0.4mg/0.4ml and 4 mg/0.1 ml. 0.4mg/ml led the market revenues ($ 1530.9 million) in 2020. However, there is only a minor difference between 4mg/0.1 ml and the other dosages, which stand second in terms of 2020 revenues. The most recommended injections are dosed as 0.4mg at the start of the treatment.

Hospitals are The Primary Point of Naloxone Sales

With respect to sales channels, the market is segmented based on hospital pharmacy, outpatient retail pharmacy, online pharmacy, and others. Hospital pharmacies were the prime point of sales for naloxone in 2020, as the primary place of emergency treatment is still hospitals. For individuals who do not require hospitals, outpatient retail pharmacies remain the key point of sales. Online and other channels were not significantly popular in 2020. However, there are significant changes expected in the market trend during the forecast period of 2021 to 2029.

NA Dominates the Current Market, Significant Opportunities in APAC Region

The largest market, North America, was worth $ 1665 Mn in 2020 and is expected to grow at a CAGR of 10.4% during the forecast period of 2021 to 2030. Asia Pacific grew at the fastest rate of 11.2% CAGR from 2021 to 2030 due to emerging market potential that is promising a higher uptake of naloxone during the forecast period.Asia Pacific is observed to be the most attractive region for the naloxone market owing to a swift growth in the uptake of medicines to prevent surging death rates.APAC is evidencing an increased per capita income that makes access to opioids easy. Awareness of options for reversing opioid overdose is further expected to boost the revenues of this region during the forecast period. The key regions that are promising growth in Asia include China, Japan, Australia, Korea, and others. 

Entry of Generics Changing Competitive Dynamics in the Market

Indivior remains at the top position with respect to product portfolio and business strength. Currently Indivior holds maximum number of products directly and indirectly related to naloxone, for instance, Suboxone, Sublocade and Subutex. Suboxone patent has expired and hence generic products are being introduced in the market. Key companies in naloxone market include Indivor, Orexo, Emergent Biosolutions, Viatris, Novartis, Amphastar Pharmaceuticals, Hospira, Mundipharma, Kern Pharma, UCB and Others

Historical &Forecast Period

This research report presents the analysis of each segment from 2020 to 2030 considering 2021 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segment are calculated for the forecast period from 2021 to 2030.

Report Methodology

Market revenues and CAGR were derived from primary and secondary research. Both quantitative and qualitative trends were considered for extrapolation of market revenues. The derived market estimates were further validated from top down, bottom strategies and primary research. The scope of the market is limited to the following segments of product categories and region.

By Formulation/Route of administration (2020-2030; US$ Mn)

Parenteral
Intranasal
Sublingual

By Dosage/Strength (2020-2030; US$ Mn)

0.4mg/ml
1mg/1ml
0.4mg/0.4ml
4 mg/0.1 ml

By Sales Channel (2020-2030; US$ Mn)

hospital pharmacy
outpatient retail pharmacy
online pharmacy
others

By Region (2020-2030; US$ Mn)

North America
Europe
Asia Pacific
Latin America
Africa

Global Impact of Covid-19 Segment (2020-2021; US$ Mn)

Pre Covid-19 situation
Post Covid-19 situation

Key questions answered in this report

  • What are the key market segments in current scenario and in the future by product categories?
  • What are the key market segments in current scenario and in the future by regions?
  • What is the key impact of Covid-19 over market revenues and market determinants in the global naloxonemarket?
  • What are the primary and secondary macro and micro factors influencing the market growth currently and during the forecast period?
  • What are the primary and secondary macro and micro factors deterring the market growth currently and during the forecast period?
  • How to overcome the current market challenges and leverage the opportunities in each of the market segment?
  • Who are the key players in the operational predictive maintenance market and what are their key product categories and strategies?
  • What are the key strategies – mergers/acquisitions/R&D/strategic partnerships etc. that companies are deploying to enhance market revenues and growth?

Select License Type

$4,600
$6,600
$13,200

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1569

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.